Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 52 entries
View as:

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00051116 Org: User:
Start: 05/31/02 End: 10/31/06 Due: 10/31/07

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00179738 Org: User:
Start: 04/30/05 End: 04/30/07 Due: 04/30/08

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Phase: N/A Priority: Normal
NCT ID: NCT00405756 Org: User:
Start: 01/31/07 End: 04/30/16 Due: 04/30/17

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

Phase: N/A Priority: Normal
NCT ID: NCT00072722 Org: User:
Start: 09/30/03 End: 04/30/05 Due: 04/30/06

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00179699 Org: User:
Start: 09/30/05 End: 11/30/06 Due: 11/30/07

Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00179712 Org: User:
Start: 04/30/05 End: 11/30/06 Due: 11/30/07

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00833833 Org: User:
Start: 06/30/08 End: 09/30/15 Due: 09/30/16

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Phase: N/A Priority: Normal
NCT ID: NCT02034773 Org: User:
Start: 05/31/13 End: 12/31/13 Due: 12/31/14

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

Phase: N/A Priority: Normal
NCT ID: NCT00596999 Org: User:
Start: 05/31/07 End: 12/31/13 Due: 12/31/14

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

Phase: N/A Priority: Normal
NCT ID: NCT00124943 Org: User:
Start: 07/31/05 End: 08/31/09 Due: 08/31/10

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00002127 Org: User:
Start: - End: - Due: -

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Phase: N/A Priority: Normal
NCT ID: NCT00091624 Org: User:
Start: 03/31/03 End: 09/30/07 Due: 09/30/08

Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00046527 Org: User:
Start: 06/30/01 End: - Due: -

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00126893 Org: User:
Start: 10/31/05 End: 09/30/06 Due: 09/30/07

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00064974 Org: User:
Start: 06/30/03 End: 02/28/07 Due: 02/28/08

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

Phase: N/A Priority: Normal
NCT ID: NCT00067743 Org: User:
Start: 08/31/03 End: 08/31/07 Due: 08/31/08

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00040391 Org: User:
Start: 06/30/02 End: - Due: -

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT01908387 Org: User:
Start: 07/31/13 End: 07/31/15 Due: 07/31/16

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00380835 Org: User:
Start: - End: 12/31/07 Due: 12/31/08

Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT02655159 Org: User:
Start: 01/31/16 End: 08/31/16 Due: 08/31/17

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02011113 Org: User:
Start: 12/31/13 End: 09/30/15 Due: 09/30/16

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00046514 Org: User:
Start: 06/30/01 End: - Due: -

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00073723 Org: User:
Start: 12/31/03 End: 01/31/07 Due: 01/31/08

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00474188 Org: User:
Start: 05/31/07 End: 12/31/08 Due: 12/31/09

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01032291 Org: User:
Start: 12/31/09 End: 01/31/11 Due: 01/31/12